Distinguishing Mycobacterium abscessus subspecies presents significant diagnostic challenges due to their genetic homogeneity and variability in analytical platforms. Our research combines matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry with machine learning (ML) approaches to enhance discrimination accuracy, utilizing 325 spectra profiles from diverse European hospitals. The analytical pipeline incorporates specialized techniques for geographical data harmonization, feature selection, and balancing class representation. The best model employs support vector machines (SVMs) with ComBat correction, Boruta feature selection, and centroid clustering for class imbalance, achieving a discrimination performance of 97% F1 score and 97.17% AUC-ROC on test samples. Noteworthily, most tested models improved their discrimination performance with the approach and demonstrated consistent performance metrics with high geometric mean (GEO) and index balanced accuracy (IBA) metrics (>0.90), ensuring consistent sensitivity and specificity across all subspecies. SHAP (SHapley Additive exPlanations) validated the biological relevance of selected spectral features, particularly improving discrimination of the diagnostically challenging M. abscessus subsp. bolletii. This work advances the state-of-the-art in M. abscessus classification, providing a scalable analytical framework for enhanced microbial diagnostics and targeted antimicrobial therapy selection.
In oncology, there is a critical need for robust biomarkers that can be easily translated into the clinic. We introduce a novel approach using paired differential gene expression analysis for biological feature selection in machine learning models, enhancing robustness and interpretability while accounting for patient variability. This method compares primary tumor tissue with the same patient’s healthy tissue, improving gene selection by eliminating individual-specific artifacts. A focus on carcinoma was selected due to its prevalence and the availability of the data; we aim to identify biomarkers involved in general carcinoma progression, including less-researched types. Our findings identified 27 pivotal genes that can distinguish between healthy and carcinoma tissue, even in unseen carcinoma types. Additionally, the panel could precisely identify the tissue-of-origin in the eight carcinoma types used in the discovery phase. Notably, in a proof of concept, the model accurately identified the primary tissue origin in metastatic samples despite limited sample availability. Functional annotation reveals these genes’ involvement in cancer hallmarks, detecting subtle variations across carcinoma types. We propose paired differential gene expression analysis as a reference method for the discovering of robust biomarkers.
Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain ( IGH ) and B‐cell lymphoma 3 ( BCL3 ) loci. Aiming at comprehensive molecular characterization of IGH :: BCL3‐ positive B‐cell neoplasms, we here investigated samples from 84 patients using fluorescence in situ hybridization (FISH), whole‐genome and targeted sequencing, and DNA methylation analyses. Junctional sequences obtained in 27 patients showed breakpoints upstream of BCL3 in all CLL cases. IGH breaks were presumably driven by aberrant class‐switch recombination in 26/27 cases, frequently involving IGHA (12/26). Notably, 95% (78/82) of patients carried an unmutated IGHV with significant CLL stereotype subset #8 enrichment. Trisomy 12 (61%, 51/83) and mutations affecting NOTCH1 (32%, 25/79), BRAF (14%, 11/79), and FBXW7 (14%, 11/79) were frequent aberrations. DNA methylation analysis assigned 77% (51/66) of patients with IGH :: BCL3‐ translocation with at least 60% tumor cell content to the naive B‐cell‐like group but unraveled a distinct and during follow‐up stable signature resembling in part plasma cell‐like epigenetic features. A binary DNA methylation classifier using 20 CpGs could distinguish IGH :: BCL3 ‐translocated CLL samples from other CLL subtypes. In an efficacy cohort of 3832 previously untreated patients from GCLLSG trials, IGH::BCL3 was associated with shorter progression‐free survival (PFS) and overall survival (OS) in 28 patients when treated with chemoimmunotherapy, but not in those receiving venetoclax. Our findings highlight the genetic and epigenetic homogeneity of IGH :: BCL3 ‐translocated CLL samples and their differences from other types of CLL, suggesting IGH :: BCL3 leukemic B‐cell neoplasms to be a biological distinct type within the spectrum of mature lymphatic leukemia/CLL.